Sfoglia per Autore
K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting
2008-01-01 Santini, D.; Loupakis, F.; Vincenzi, B.; Perrone, G.; Graziano, F.; Floriani, I.; Maltese, P.; Stasi, I.; Canestrari, E.; Masi, G.; ONETTI MUDA, A.; Magnani, M.; Falcone, Alfredo; Ruzzo, A.; Tonini, G.
Pegfilgrastim to support chop-r chemotherapy administered every 14 days in patients (PTS) with aggressive B-cell non-Hodgkin’s lymphoma (NHL)
2008-01-01 Cupini, S.; Capochiani, E.; Bursi, S.; Landi, L.; Coltelli, L.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Stasi, I.; Dincecco, A.; Salvatore, L.; Caponi, S.; Bona, E.; Battaglini, P.; Masi, G.; Falcone, Alfredo
Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy
2008-01-01 Graziano, F.; Ruzzo, A.; Loupakis, F.; Santini, D.; Catalano, V.; Canestrari, E.; Maltese, P.; Bisonni, R.; Fornaro, L.; Baldi, G.; Masi, G.; Falcone, Alfredo; Tonini, G.; Giordani, P.; Alessandrini, P.; Giustini, L.; Vincenti, B.; Magnani, M.
Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer
2008-01-01 Graziano, Francesco; Ruzzo, Annamaria; Loupakis, Fotios; Canestrari, Emanuele; Santini, Daniele; Catalano, Vincenzo; Bisonni, Renato; Torresi, Umberto; Floriani, Irene; Schiavon, Gaia; Andreoni, Francesca; Maltese, Paolo; Rulli, Eliana; Humar, Bostjan; Falcone, Alfredo; Giustini, Lucio; Tonini, Giuseppe; Fontana, Andrea; Masi, Gianluca; Magnani, Mauro
Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target
2008-01-01 Pagliacci, A.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Galizia, E.; Pierantoni, C.; Loupakis, F.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Masi, G.; Falcone, Alfredo; Cascinu, S.
FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group
2008-01-01 Falcone, Alfredo; Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Amoroso, D.; Puglisi, M.; Fea, E.; Brunetti, I.
Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations
2008-01-01 Allegrini, G.; Bocci, Guido; Barletta, M.; Fioravanti, A.; DI DESIDERIO, T.; Loupakis, F.; Masi, G.; Baldi, G.; DI MARSICO, R.; DEL TACCA, M.; DI LEO, A.; Brandi, G.; Andreuccetti, M.; Kerbel, R.; Falcone, Alfredo
Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer
2008-01-01 Santini, D.; Vincenzi, B.; Masi, G.; Catalano, V.; Virzi, V.; Vasile, E.; Fontana, A.; Intagliata, S.; Catalano, G.; Falcone, Alfredo; Tonini, G.
Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment
2008-01-01 Loupakis, F.; Pollina, L.; Stasi, I.; Masi, G.; Funel, N.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Cascinu, S.; Falcone, Alfredo
EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach
2008-01-01 Loupakis, F.; Vasile, E.; Santini, D.; Masi, G.; Falcone, Alfredo; Graziano, F.
A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer
2008-01-01 Fornaro, L.; Masi, G.; Bursi, S.; Loupakis, F.; Vasile, E.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; DI PAOLO, Antonello; Bocci, Guido; DEL TACCA, M.; Falcone, Alfredo
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice
2008-01-01 Santini, D.; Loupakis, F.; Vincenzi, B.; Floriani, I.; Stasi, I.; Canestrari, E.; Rulli, E.; Maltese, P. E.; Andreoni, F.; Masi, G.; Graziano, F.; Baldi, G. G.; Salvatore, L.; Russo, A.; Perrone, G.; Tommasino, M. R.; Magnani, M.; Falcone, Alfredo; Tonini, G.; Ruzzo, A.
Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer
2008-01-01 Masi, G.; Vasile, E.; Loupakis, F.; Bursi, S.; Ricci, S.; Petrini, Iacopo; Fontana, A.; Allegrini, G.; Falcone, Alfredo
First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first?
2008-01-01 Loupakis, F.; Masi, G.; Vasile, E.; Falcone, Alfredo
Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction
2008-01-01 Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano
A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients.
2008-01-01 Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido
Pharmacogenetic profiling for anti-Epidermal Growth Factor Receptor therapy in patients with refractory advanced colorectal cancer
2008-01-01 Graziano, F.; Ruzzo, A.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V.; Bisonni, R.; Torresi, U.; Floriani, I.; Schiavon, G.; Andreoni, F.; Maltese, P.; Rulli, E.; Humar, B.; Falcone, Alfredo; Giustini, L.; Tonini, G.; Masi, G.; Silva, R.; Magnani, M.
First-line systemic chemotherapy with folfoxiri followed by radical surgical resection of metastases for the treatment of unresectable metastatic colorectal cancer patients
2009-01-01 Vasile, E.; Masi, G.; Loupakis, F.; Cupini, S.; Baldi, G. G.; Fornaro, L.; Stasi, I.; Salvatore, L.; Falcone, Alfredo
Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan
2009-01-01 Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Loupakis, F.; Zaniboni, A.; Berardi, R.; Pierantoni, C.; Masi, G.; Falcone, Alfredo; Cascinu, S.
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
2009-01-01 Loupakis, F; Ruzzo, A; Cremolini, Chiara; Vincenzi, B; Salvatore, L; Santini, D; Masi, G; Stasi, I; Canestrari, E; Rulli, E; Floriani, I; Bencardino, K; Galluccio, N; Catalano, V; Tonini, G; Magnani, M; Fontanini, Gabriella; Basolo, Fulvio; Falcone, Alfredo; Graziano, F.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| K-RAS status in primary colorectal tumours correlate with K-RAS status in related metastatic sites: implications for treatment with anti-EGFR antibodies in clinical setting | 1-gen-2008 | Santini, D.; Loupakis, F.; Vincenzi, B.; Perrone, G.; Graziano, F.; Floriani, I.; Maltese, P.; Stasi, I.; Canestrari, E.; Masi, G.; ONETTI MUDA, A.; Magnani, M.; Falcone, Alfredo; Ruzzo, A.; Tonini, G. | |
| Pegfilgrastim to support chop-r chemotherapy administered every 14 days in patients (PTS) with aggressive B-cell non-Hodgkin’s lymphoma (NHL) | 1-gen-2008 | Cupini, S.; Capochiani, E.; Bursi, S.; Landi, L.; Coltelli, L.; Giuntini, N.; LO DICO, M.; Mazzoni, E.; Baldi, G. G.; Barletta, M. T.; Fornaro, L.; Stasi, I.; Dincecco, A.; Salvatore, L.; Caponi, S.; Bona, E.; Battaglini, P.; Masi, G.; Falcone, Alfredo | |
| Liver-only metastatic colorectal cancer patients and thymidylate synthase polymorphisms for predicting response to 5-fluorouracil-based chemotherapy | 1-gen-2008 | Graziano, F.; Ruzzo, A.; Loupakis, F.; Santini, D.; Catalano, V.; Canestrari, E.; Maltese, P.; Bisonni, R.; Fornaro, L.; Baldi, G.; Masi, G.; Falcone, Alfredo; Tonini, G.; Giordani, P.; Alessandrini, P.; Giustini, L.; Vincenti, B.; Magnani, M. | |
| Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer | 1-gen-2008 | Graziano, Francesco; Ruzzo, Annamaria; Loupakis, Fotios; Canestrari, Emanuele; Santini, Daniele; Catalano, Vincenzo; Bisonni, Renato; Torresi, Umberto; Floriani, Irene; Schiavon, Gaia; Andreoni, Francesca; Maltese, Paolo; Rulli, Eliana; Humar, Bostjan; Falcone, Alfredo; Giustini, Lucio; Tonini, Giuseppe; Fontana, Andrea; Masi, Gianluca; Magnani, Mauro | |
| Epidermal growth factor receptor (EGFR) gene promoter methylation in primari colorectal tumours and corresponding metastatic sites: a new perspective for an “old”therapeutic target | 1-gen-2008 | Pagliacci, A.; Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Galizia, E.; Pierantoni, C.; Loupakis, F.; Berardi, R.; Zaniboni, A.; Quadri, A.; Zorzi, F.; Biscotti, T.; Labianca, R.; Masi, G.; Falcone, Alfredo; Cascinu, S. | |
| FOLFOXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab (BV) in the first-line treatment of metastatic colorectal cancer (mCRC): A phase II study by the G.O.N.O. group | 1-gen-2008 | Falcone, Alfredo; Masi, G.; Loupakis, F.; Vasile, E.; Ciarlo, A.; Cavaciocchi, D.; Amoroso, D.; Puglisi, M.; Fea, E.; Brunetti, I. | |
| Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations | 1-gen-2008 | Allegrini, G.; Bocci, Guido; Barletta, M.; Fioravanti, A.; DI DESIDERIO, T.; Loupakis, F.; Masi, G.; Baldi, G.; DI MARSICO, R.; DEL TACCA, M.; DI LEO, A.; Brandi, G.; Andreuccetti, M.; Kerbel, R.; Falcone, Alfredo | |
| Phase II capecitabine and gemcitabine fixed dose rate (FDR) in patients with advanced pancreatic cancer | 1-gen-2008 | Santini, D.; Vincenzi, B.; Masi, G.; Catalano, V.; Virzi, V.; Vasile, E.; Fontana, A.; Intagliata, S.; Catalano, G.; Falcone, Alfredo; Tonini, G. | |
| Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primari tumors as predictors of activity of cetuximab plus irinotecan treatment | 1-gen-2008 | Loupakis, F.; Pollina, L.; Stasi, I.; Masi, G.; Funel, N.; Scartozzi, M.; Petrini, Iacopo; Santini, D.; Cascinu, S.; Falcone, Alfredo | |
| EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: rationale for a pharmacogenomic approach | 1-gen-2008 | Loupakis, F.; Vasile, E.; Santini, D.; Masi, G.; Falcone, Alfredo; Graziano, F. | |
| A dose finding and pharmacokinetic study of capecitabine in combination with oxaliplatin and irinotecan in metastatic colorectal cancer | 1-gen-2008 | Fornaro, L.; Masi, G.; Bursi, S.; Loupakis, F.; Vasile, E.; Antonuzzo, A.; Chiara, S.; Pfanner, E.; DI PAOLO, Antonello; Bocci, Guido; DEL TACCA, M.; Falcone, Alfredo | |
| High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice | 1-gen-2008 | Santini, D.; Loupakis, F.; Vincenzi, B.; Floriani, I.; Stasi, I.; Canestrari, E.; Rulli, E.; Maltese, P. E.; Andreoni, F.; Masi, G.; Graziano, F.; Baldi, G. G.; Salvatore, L.; Russo, A.; Perrone, G.; Tommasino, M. R.; Magnani, M.; Falcone, Alfredo; Tonini, G.; Ruzzo, A. | |
| Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer | 1-gen-2008 | Masi, G.; Vasile, E.; Loupakis, F.; Bursi, S.; Ricci, S.; Petrini, Iacopo; Fontana, A.; Allegrini, G.; Falcone, Alfredo | |
| First-line chemotherapy in metastatic colorectal cancer: new approaches and therapeutic algorithms. Always hit hard first? | 1-gen-2008 | Loupakis, F.; Masi, G.; Vasile, E.; Falcone, Alfredo | |
| Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction | 1-gen-2008 | Bocci, Guido; DI PAOLO, Antonello; Masi, G.; Fornaro, L.; Allegrini, G.; Falcone, Alfredo; DEL TACCA, M.; Danesi, Romano | |
| A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. | 1-gen-2008 | Allegrini, G.; Falcone, Alfredo; Fioravanti, Anna; Barletta, M. T.; Orlandi, Paola; Loupakis, F.; Cerri, E.; Masi, G.; DI PAOLO, Antonello; Kerbel, R. S.; Danesi, Romano; Del Tacca, M.; Bocci, Guido | |
| Pharmacogenetic profiling for anti-Epidermal Growth Factor Receptor therapy in patients with refractory advanced colorectal cancer | 1-gen-2008 | Graziano, F.; Ruzzo, A.; Loupakis, F.; Canestrari, E.; Santini, D.; Catalano, V.; Bisonni, R.; Torresi, U.; Floriani, I.; Schiavon, G.; Andreoni, F.; Maltese, P.; Rulli, E.; Humar, B.; Falcone, Alfredo; Giustini, L.; Tonini, G.; Masi, G.; Silva, R.; Magnani, M. | |
| First-line systemic chemotherapy with folfoxiri followed by radical surgical resection of metastases for the treatment of unresectable metastatic colorectal cancer patients | 1-gen-2009 | Vasile, E.; Masi, G.; Loupakis, F.; Cupini, S.; Baldi, G. G.; Fornaro, L.; Stasi, I.; Salvatore, L.; Falcone, Alfredo | |
| Correlation of insulin-like growth factor 1 (IGF-1) expression and clinical outcome in K-RAS wild-type colorectal cancer patients treated with cetuximab-irinotecan | 1-gen-2009 | Scartozzi, M.; Bearzi, I.; Mandolesi, A.; Loupakis, F.; Zaniboni, A.; Berardi, R.; Pierantoni, C.; Masi, G.; Falcone, Alfredo; Cascinu, S. | |
| KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer | 1-gen-2009 | Loupakis, F; Ruzzo, A; Cremolini, Chiara; Vincenzi, B; Salvatore, L; Santini, D; Masi, G; Stasi, I; Canestrari, E; Rulli, E; Floriani, I; Bencardino, K; Galluccio, N; Catalano, V; Tonini, G; Magnani, M; Fontanini, Gabriella; Basolo, Fulvio; Falcone, Alfredo; Graziano, F. |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile